20th week of 2013 patent applcation highlights part 42 |
Patent application number | Title | Published |
20130122001 | ANTIBODY VARIANTS WITH ENHANCED COMPLEMENT ACTIVITY - The present invention relates to novel Fc variants that comprise at least one novel amino acid residue which may provide for enhanced effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc receptor or ligand (e.g., Fc gamma R, C1q). Additionally, the Fc variants have altered complement dependent cytotoxicity (CDC) activity and/or antibody-dependent cell-mediated cytotoxicity (ADCC). The invention further provides methods and protocols for the application of said Fc variants, particularly for therapeutic purposes. | 2013-05-16 |
20130122002 | METHODS FOR CANCER MANAGEMENT TARGETING CO-029 - The present disclosure relates to a Co-029 inhibitor for inhibiting the migration of cancer cells which express Co-029. The disclosure relates to a Co-029 inhibitor for the treatment of cancer and/or the prevention of cancer metastasis and pharmaceutical compositions comprising said inhibitor and provides Co-029 antibodies. The disclosure provides a method for predicting the response of a patient afflicted with or susceptible to be afflicted with cancer to a medical treatment with a Co-029 inhibitor, a method for diagnosing a cancer in a patient and a method for predicting the survival in a cancer patient. | 2013-05-16 |
20130122003 | METHODS OF INHIBITING TUMOR GROWTH BY ANTAGONIZING IL-6 RECEPTOR - The present invention provides methods for inhibiting or attenuating tumor growth in a subject by administering an IL-6 antagonist to the subject. In certain embodiments, the methods of the invention are used to inhibit the growth of an anti-VEGF-resistant tumor in a subject. The IL-6 antagonist may be, e.g., an antibody that specifically binds IL-6R. The IL-6 antagonist may be administered in combination with a VEGF antagonist, and/or an EGFR antagonist. | 2013-05-16 |
20130122004 | METHODS AND COMPOSITIONS USING FGF23 VARIANT POLYPEPTIDES - The present disclosure is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The fusion polypeptides of the disclosure include FGF23 or an active fragment thereof. In one embodiment, the fusion polypeptide comprises (a) a polypeptide comprising fibroblast growth factor 23 (FGF23), or a functionally active variant or derivative thereof, wherein FGF23 has a mutation at one or more of the positions Q156, C206 and C244; and (b) either a modified Fc fragment having decreased affinity for Fc-gamma-receptor and/or increased serum half-life, or a polypeptide comprising at least one extracellular subdomain of a Klotho protein, or a functionally active variant or derivative thereof; and, optionally (c) a linker. The Klotho fusion proteins are useful in the treatment and prevention of a variety of age-related conditions and metabolic disorders. In another embodiment, the fusion polypeptide comprises a FGF (such as FGF23), or a functionally active variant or derivative thereof and a modified Fc fragment, or a functionally active variant or derivative thereof. In various embodiments of the fusion polypeptides, FGF23 has mutations which decrease aggregation and protease-mediated cleavage. | 2013-05-16 |
20130122005 | ANTICANCER COMBINATION THERAPY - The invention describes anti-cancer therapies comprising using a dual Aurora kinase/MEK inhibitor and an anti-IGF antibody, each as described herein. | 2013-05-16 |
20130122006 | ANTI-CD160 SPECIFIC ANTIBODIES FOR THE TREATMENT OF EYE DISORDERS BASED ON NEOANGIOGENESIS - The present invention relates to the use of at least one anti-CD 160 antibody, preferably a compound selected from CL1-R2 monoclonal antibody (which may be obtained by the hybridoma CNCM I-3204), its conservative fragments and its conservative derivatives, for preparing a drug designed to treat neovascular eye diseases. | 2013-05-16 |
20130122007 | Compositions and Methods for Increasing Muscle Mass and Muscle Strength by Specifically Antagonizing GDF8 and or Activin A - The present invention provides compositions and methods which involve specifically antagonizing GDF8 and Activin A. In certain embodiments, compositions are provided which comprise a GDF8-specific binding protein and an Activin A-specific binding protein. For example, the invention includes compositions comprising an anti-GDF8 antibody and an anti-Activin A antibody. In other embodiments, antigen-binding molecules are provided which comprise a GDF8-specific binding domain and an Activin A-specific binding domain. For example, the invention includes bispecific antibodies that bind GDF8 and Activin A. The compositions of the present invention are useful for the treatment of diseases and conditions characterized by reduced muscle mass or strength, as well as other conditions which are treatable by antagonizing GDF8 and/or Activin A activity. | 2013-05-16 |
20130122008 | Anti-IL 1- Antibody Combination Therapy - The present invention relates to a new combination comprising a therapeutically effective amount of an anti-IL1β antibody or an antigen-binding fragment thereof and at least one anti-diabetic agent. The anti-diabetic agent can be selected from the group consisting of insulin signaling pathway modulators, such as inhibitors of protein tyrosine phosphatases (PTPases), non-small molecule mimetic compounds and inhibitors of glutamine-fructose-6-phosphate amidotransferase (GFAT), DPP-IV inhibitors, agents influencing a deregulated hepatic glucose production, like inhibitors of glucose-6-phosphatase (G6Pase), inhibitors of fructose-1,6-bisphosphatase (F-1,6-BPase), inhibitors of glycogen phosphorylase (GP), glucagon receptor antagonists and inhibitors of phosphoenolpyruvate carboxykinase (PEPCK), pyruvate dehydrogenase kinase (PDHK) inhibitors, insulin sensitivity enhancers, insulin secretion enhancers, α-glucosidase inhibitors, inhibitors of gastric emptying, insulin, and α | 2013-05-16 |
20130122009 | Engineered Anti-IL-23p19 Antibodies - Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders. | 2013-05-16 |
20130122010 | Diagnostic Methods Based on Somatically Acquired Rearrangement - A monitoring method comprising identifying a somatically acquired genomic rearrangement associated with a disease state in a patient by genome-wide analysis of the nucleic acid of that patient and monitoring the changes in levels of nucleic acid containing the genomic rearrangement, and/or quantifying the levels of nucleic acid containing the genomic rearrangement as a marker for the progression or severity of a disease in that patient is described. Use of a monitoring process of the invention in assessment of efficacy of a therapy and use of a patient specific genomic rearrangement as a biomarker for disease progression in that patient are also described. | 2013-05-16 |
20130122011 | Multiple-variable dose regimen for treating TNFa-related disorders - Multiple-variable dose methods for treating TNFα-related disorders, including Crohn's disease and psoriasis, comprising administering TNFα inhibitors, including TNFα antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase. | 2013-05-16 |
20130122012 | Anti-IL-6/IL-6R Antibodies and Methods of Use Thereof - This invention provides fully human monoclonal antibodies that recognize the IL-6/IL-6R complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic. | 2013-05-16 |
20130122013 | ANTI-FERROPORTIN 1 MONOCLONAL ANTIBODIES AND USES THEREOF - Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of human FPN1, and which are effective in maintaining or increasing the transport of iron out of mammalian cells and/or maintaining or increasing the level of serum iron, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a subject in vivo. | 2013-05-16 |
20130122014 | HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1) - The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies. | 2013-05-16 |
20130122015 | ANTIBODY AND METHODS FOR SELECTIVE INHIBITION OF T-CELL RESPONSES - The present invention provides compositions, methods, and assays for treating an inflammatory and/or autoimmune disease, and/or transplanted tissue rejection using anti-αβ TCR antibodies and antibody fragments. Anti-αβ TCR antibodies are antibodies which bind to a αβ TCR. Anti-αβ TCR antibodies produced by the hybridoma TOL101 MCB are also provided. Methods for treatment of an inflammatory disease, an autoimmune disease and for tissue transplant rejection using therapeutic dosing regimen of anti-αβ TCR antibodies and antibody fragments and for upregulating the numbers of Treg T-cells are also provided | 2013-05-16 |
20130122016 | Methods and Compositions for Prognosing, Detecting, and Treating Age-Related Macular Degeneration - The invention provides methods and compositions for determining whether a subject is at risk of developing age-related macular degeneration, for example, the wet or neovascular form of age-related macular degeneration. The method involves determining whether the subject has a protective variant and/or a risk variant at a polymorphic site in the HTRA1 gene. In addition, the invention provides a method of treating or slowing the progression of age-related macular degeneration by reducing the expression of the HTRA1 gene, or reducing the biological activity of the HTRA1 gene product. | 2013-05-16 |
20130122017 | Osteoprotegerin in Neuroprotection - Methods for treating neurodegeneration, e.g., sensorineural hearing loss, or a demyelinating disease, using bisphosphonates, ERK kinase inhibitors, and osteoprotegerin (OPG) proteins or nucleic acids. | 2013-05-16 |
20130122018 | HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha - Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K | 2013-05-16 |
20130122019 | ANTI-HUMAN ALPHA9 INTEGRIN ANTIBODY AND USE THEREOF - The present invention relates to an anti-human α9 integrin antibody. More particularly, the present invention relates to: a monoclonal antibody, a chimeric antibody, a humanized antibody and a human antibody that specifically recognize human α9 integrin; a hybridoma cell that produces the monoclonal antibody; a method for producing the monoclonal antibody; a method for producing the hybridoma cell; a therapeutic agent comprising the anti-human α9 integrin antibody; a diagnostic agent comprising the human α9 integrin antibody; and a method for screening for a compound that inhibits the activity of human α9 integrin. | 2013-05-16 |
20130122020 | ANTIBODIES SPECIFIC FOR TROP-2 AND THEIR USES - The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer. | 2013-05-16 |
20130122021 | B7-H3 IN CANCER - Methods of determining the prognosis of a subject with cancer and determining risk of cancer progression by assessing expression of B7-H3. Methods of reducing B7-H3 levels and/or activity. | 2013-05-16 |
20130122022 | SEQUENCE OF STRO-1 ANTIBODY VARIABLE REGION - The amino acid sequence of the heavy chain polypeptide and the light chain polypeptide of the STRO-1 antibody is disclosed. Also disclosed are methods for detecting and isolating cells expressing the STRO-1 cell surface protein. | 2013-05-16 |
20130122023 | NOVEL LONG-ACTING GLUCAGON CONJUGATE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME FOR THE PREVENTION AND TREATMENT OF OBESITY - Disclosed is a novel long-acting glucagon conjugate in which glucagon or its derivative is covalently linked to a polymer carrier via a non-peptide linker, and a pharmaceutical composition comprising the same as an effective ingredient useful for the prevention and treatment of obesity. Since the long-acting glucagon conjugate of the present invention shows improved in vivo durability and stability, when used in combination with an anti-obesity drug, it is possible to induce synergistic effects on the loss of body weight and decrease in food intake without causing any side-effects such as fluctuation in blood glucose level. Accordingly, the long-acting peptide conjugate of the present invention is very effective for the prevention and treatment of obesity. | 2013-05-16 |
20130122024 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF - The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target mesothelin, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures. | 2013-05-16 |
20130122025 | METHOD OF RAPIDLY PRODUCING IMPROVED VACCINES FOR ANIMALS - A method of quickly producing a vaccine for a biotype of pathogenic microorganism is described, where a nucleic acid molecule or fragment thereof is obtained from a biological sample from an animal exposed to the microorganism, a protective molecule is prepared based on the nucleic acid molecule of interest or fragment thereof, and administered to an animal which has been or is as risk of being exposed to the microorganism. A protective response to the biotype of the microorganism is obtained in the animal. | 2013-05-16 |
20130122026 | DNA VACCINE FOR ALZHEIMER'S DISEASE - The present invention aims to provide a DNA vaccine for Alzheimer's disease. | 2013-05-16 |
20130122027 | NEOEPITOPE DETECTION OF DISEASE USING PROTEIN ARRAYS - A biosensor for use in detecting the presence of diseases, the biosensor comprising a detector for detecting a presence of at least one marker indicative of a specific disease. A method of determining efficacy of a pharmaceutical for treating a disease or staging disease by administering a pharmaceutical to a sample containing markers for a disease, detecting the amount of at least one marker of the disease in the sample, and analyzing the amount of the marker in the sample, whereby the amount of marker correlates to pharmaceutical efficacy or disease stage. Markers for gynecological disease. An immuno-imaging agent comprising labeled antibodies, whereby the labeled antibodies are isolated and reactive to proteins overexpressed in vivo. Informatics software for analyzing the arrays, the software including analyzing means for analyzing the arrays. | 2013-05-16 |
20130122028 | NOVEL VACCINE THAT TARGETS TUMOR VESSELS AS AN EFFICIENT TOOL IN TUMOR THERAPY - The invention relates to a composition for the treatment of various cancers. The composition is a vaccine containing sequences of EDB, EDA, annexin A1, endosialin, C domain of tenascin C or magic roundabout (MR) or fragments thereof as single or in a combination coupled to one or several heterologous foreign carrier molecules. The vaccine will produce antibodies that are directed against self proteins which are preferentially expressed in and around tumor vessels. The vaccine is preferably administrated together with an adjuvant. | 2013-05-16 |
20130122029 | CANCER VACCINE - The present invention is directed to provide a cancer vaccine used for preventing and treating cancers. Provided are a peptide consisting of a sequence of SEQ ID No. 1 (KMHIRSHTL) or SEQ ID No. 2 (RTFSRMSLL) and capable of efficiently inducing cancer immunity, an antigen-presenting cell presenting this peptide on its cell surface, a T cell induced by this antigen-presenting cell as well as a cancer vaccine containing these peptides, an expression vector capable of expressing either of these peptides, the antigen-presenting cell presenting either of these peptides or the T cell induced by the antigen-presenting cell, and a method of treating and preventing cancers using the cancer vaccine. | 2013-05-16 |
20130122030 | S. EPIDERMIDIS ANTIGENS - Hyperimmune serum reactive antigens and fragments thereof are disclosed. In addition, methods for isolating such antigens and specific uses thereof, including the treatment of | 2013-05-16 |
20130122031 | HMGB1-DERIVED PEPTIDES ENHANCE IMMUNE RESPONSE TO ANTIGENS - The invention provides an immunostimulatory peptide containing the amino acid sequence SAFFLFCSE and uses thereof. | 2013-05-16 |
20130122032 | RECOMBINANT NANOPARTICLE RSV F VACCINE FOR RESPIRATORY SYNCYTIAL VIRUS - The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection. | 2013-05-16 |
20130122034 | STAPHYLOCOCCUS AUREUS SURFACE PROTEIN SA1789 AND PROTECTIVE VACCINE BASED THEREON - The novel protein SA1789 from | 2013-05-16 |
20130122035 | HERBAL COMPOSITION FOR TREATING CANCER - An herbal composition and a method for treating cancer, especially for lung cancer, useful for enhancing the quality of life. | 2013-05-16 |
20130122036 | Methods And Compositions Useful For Treating Fitzpatrick Type IV, V Or VI Skin - Compositions comprising a moisturizing agent, a desquamating agent, a mattifying agent and an agent that increases skin luminosity are disclosed herein. The compositions are useful for moisturizing, desquamating, mattifying, and increasing the luminosity in skin of an individual having a Fitzpatrick Skin Type IV, V, or VI. Also disclosed are methods for moisturizing, desquamating, mattifying, and increasing the luminosity in skin, comprising administering to an individual having a Fitzpatrick Skin Type IV, V, or VI, the present compositions. | 2013-05-16 |
20130122037 | Vault Compositions for Immunization - Methods and compositions are provided herein for immunizing a subject by administering to the subject an effective amount of an immunogenic peptide or an immunogenic fragment or variant thereof incorporated within a vault-like particle carrier. The methods and compositions advantageously exhibit enhanced ability to induce cell-mediated immunity and/or antibody-based immunity. | 2013-05-16 |
20130122038 | HETEROLOGOUS PRIME-BOOST IMMUNIZATION USING MEASLES VIRUS-BASED VACCINES - The invention provides reagents and methods for heterologous prime-boost immunization regimens. In particular, the invention provides reagents and methods for use in a paramyxovirus-based prime and adenovirus-based boost immunization system, wherein the immunization induces an immune response to a foreign antigen. | 2013-05-16 |
20130122039 | V. Cholera hypereexpressing recombinant cholera toxin B subunit showing dual immunogenicity - Immunogenic compositions imparting dual protection against enterotoxigenic labile toxin (LT)-expressing | 2013-05-16 |
20130122040 | FERMENTATION MEDIA FREE OF ANIMAL-DERIVED COMPONENTS FOR PRODUCTION OF DIPHTHERIA TOXOIDS SUITABLE FOR HUMAN VACCINE USE - The present invention relates to a fermentation medium for cultivating | 2013-05-16 |
20130122041 | ATTENUATED EHRLICHIOSIS VACCINE - The present invention relates to an attenuated strain of | 2013-05-16 |
20130122042 | BENZONAPTHYRIDINE COMPOSITIONS AND USES THEREOF - The present invention generally relates to compositions comprising benzonapthyridine small molecule immune potentiators (SMIPs) that are capable of stimulating or modulating an immune response in a subject that has had pre- or post-exposure to a pathogen such as hemorrhagic fever virus. Also provided are methods of preparing and using the SMIP compositions of the invention. | 2013-05-16 |
20130122043 | MODIFIED POLYPEPTIDES AND PROTEINS AND USES THEREOF - The present invention provides modified multi-chain and multi-subunit proteins and methods for making them. In some protease embodiments the proteins are modified AB | 2013-05-16 |
20130122044 | NOVEL INTERFERON-ALPHA-PRODUCING BONE MARROW DENDRITIC CELLS - A novel dendritic cell type has been identified within bone marrow, termed myelos interferon dendritic cells (miDC). These novel cells possess the high IFN-alpha producing activity of pDC, but they also display a wide TLR responsiveness along with T-cell stimulation capacities that more closely resemble the conventional DC populations. Moreover, these cells appear less prone to apoptosis upon activation stimuli, including viruses. These cells constitute a novel bone marrow innate immune cell type, ideally geared to linking innate and adaptive immune responses via their potent IFN-alpha production and high cell stimulatory capacity. | 2013-05-16 |
20130122045 | Cross-Protective Influenza Vaccine - The invention relates to a method for preventing or treating an influenza virus infection in a subject, the method comprising administering to the subject a therapeutically effective amount of a gamma-irradiated influenza virus, wherein the virus comprises an A/Port Chalmers/1/73 (A/PC) strain backbone of PB2, PB1, PA, NP, M1, M2 and NEP proteins. | 2013-05-16 |
20130122046 | REGULATORY FACTOR OF FOXP3 AND REGULATORY T CELLS AND USE THEREOF - Use of an ubiquitination pathway-related factor, its agonist or antagonist in the preparation of a composition for regulating FOXP3, IL-2, and/or IFN-γ activity, in which the ubiquitination pathway-related factor is selected from: Toll-like receptor, ubiquitin ligase, pro-inflammatory cytokine family receptor, and/or its coding sequence. The new type of regulatory factors can regulate regulatory T cells and immune system by regulating FOXP3, IL-2, and/or IFN-γ activity. The regulatory factors and their derivatives can also be used as immunoadjuvant for treating or preventing major diseases (such as, infectious diseases and tumor, etc). | 2013-05-16 |
20130122047 | STREPTOCOCCUS PYOGENES ANTIGENS - The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from | 2013-05-16 |
20130122048 | Tumor Cell-Based Cancer Immunotherapeutic Compositions and Methods - The present invention is based, in part, on the discovery that immunotherapy using cell-based tumor cells genetically modified to express heat shock proteins is particularly effective in preventing, prognosing and/or treating cancer (e.g., ovarian cancer). Accordingly, the invention relates to compositions, kits, and methods for preventing, prognosing and/or treating cancer (e.g., ovarian cancer). | 2013-05-16 |
20130122049 | Dendritic Cells Loaded With Heat Shocked Melanoma Cell Bodies - The present invention includes compositions and methods for the isolation, purification and preparation of immunogenic antigens for the production of customized cancer vaccines that include dendritic cells that are contacted with an antigen that includes heat-shocked cancer cells. | 2013-05-16 |
20130122050 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE - Pharmaceutical compositions and methods are provided for treating diabetes and/or restoring β-cell mass and function in a mammal in need thereof. Type 1 diabetes mellitus (T1 DM) is an autoimmune disorder characterized by immune damage to pancreatic beta-cells. Lisofylline analogs (LSF analogs) are immunomodulators that reduce interlukin 12 signaling and reduce the onset of T1 DM in non-obese diabetic (NOD) mice. A combination therapy with both LSF analog (pretreatment) and INGAP provides protection from autoimmune destruction. The concomitant or combination of an LSF analog and INGAP after pre-treatment with an LSF analog is an effective therapy for a disease or condition resulting from the loss of pancreatic islet cells or insulin production in a mammal. | 2013-05-16 |
20130122051 | Methods of preparing progesterone pharmaceutical compositions - The invention provides a method of preparing a pharmaceutical composition comprising: (a) combining progesterone particles with a liquid carrier to provide a mixture; (b) wet-milling the mixture to provide a wet-milled progesterone composition; and (c) processing the wet-milled progesterone composition to provide a pharmaceutical composition. Pharmaceutical compositions prepared by the method are also provided. | 2013-05-16 |
20130122052 | ANTIBODY MEDIATED OSSEOUS REGENERATION - The invention relates to the field of immunologically reactive molecules used to improve implantable medical devices. Immobilization of selected antibody molecules onto the surface of medical implants enable localization and concentration of in vivo growth factors in a timely manner to enhance the wound healing process following implantation of the device. When in vivo BMP-2 growth factor was captured on an implant device by attached monoclonal antibodies, the biological activity of BMP-2 was enhanced in the vicinity of the implant device. BMP-2 growth factor-specific antibody molecules or their fragments when immobilized on titanium dental or orthopedic implants improve osseo-integration. | 2013-05-16 |
20130122053 | SYNTHETIC TRITERPENOIDS AND TRICYCLIC-BIS-ENONES FOR USE IN STIMULATING BONE AND CARTILAGE GROWTH - The present invention concerns methods for stimulating the growth and repair of bone and cartilage using synthetic triterpenoids and tricyclic-bis-enones. Examples of suitable triterpenoids include CDDO, CDDO-Me, CDDO-Im, and CDDO-Ethylamide. Examples of tricyclic-bis-enones include TBE-31 and TBE-34. | 2013-05-16 |
20130122054 | LIPID MEMBRANE STRUCTURE HAVING INTRANUCLEAR MIGRATING PROPERTY - A lipid membrane structure for delivering a substance into a nucleus of a cell, wherein lipid membrane is modified with (a) a polypeptide comprising the amino acid sequence of SEQ ID NO: 1, and/or (b) a polypeptide consisting of an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 1, but including deletion and/or substitution and/or insertion of one or several amino acid residues, and having an activity of promoting migration of the lipid membrane structure into a nucleus of a cell, which can efficiently deliver a nucleic acid into a nucleus of an immunocyte such as dendritic cell. | 2013-05-16 |
20130122055 | Anionic Charge-Dynamic Polymers for Release of Cationic Agents - Materials and Methods for the generation of polyelectrolyte multilayers that can erode to release cationic components. The multilayers comprise layers that contain one or more cations and one or more charge-dynamic anionic polymers. Charge-dynamic anionic polymers contain side chains having removable functional groups. Removal of the functional groups results in a change in the net change in the charge of the polymer which can disrupt interactions between cations and the anionic polymers and facilitate release of cations. | 2013-05-16 |
20130122056 | Ratiometric Combinatorial Drug Delivery - The present teachings include ratiometric combinatorial drug delivery including nanoparticles, multi-drug conjugates, pharmaceutical compositions, methods of producing such compositions and methods of using such compositions, including in the treatment of diseases and conditions using drug combinations. | 2013-05-16 |
20130122057 | Organophosphorous, Multivalent Metal Compounds, and Bioactive Glass Material Macromolecular Network Compositions and Methods - Cements containing certain small molecule amino acid phosphate compounds such as phosphoserine and certain multivalent metal compounds such as but not limited to calcium phosphate have been found to have improved properties and form a macromolecular network in the presence of a bioactive glass material that contain silicates, phosphates, and calcium salts which can be involved in the formation of bonding sites. | 2013-05-16 |
20130122058 | ENGINEERING OF POLYMER-STABILIZED NANOPARTICLES FOR DRUGS WITH LOG P VALUES BELOW 6 BY CONTROLLED ANTISOLVENT PRECIPITATION - The present invention provides organic nanoparticles that include a molecule having a Log P value of about 3 or above, an amphiphilic diblock copolymer or a surfactant, and a pharmaceutically-acceptable hydrophilic polymer. The present invention also provides methods of making these nanoparticles, e.g., by flash nanoprecipitation, with control over particle size and surface properties. The methods of the present invention provide a means for co-precipitating a water-insoluble compound with an amphiphilic stabilizer within a few milliseconds. The nanoparticles of the present invention exhibit high drug loading, e.g., 50% w/w, and can be produced with a mean particle size less than 200 nm and with a narrow particle size distribution. | 2013-05-16 |
20130122059 | SUSPENSIONS OF CYCLOSPORIN A FORM 2 - Disclosed herein are methods of formulating cyclosporin A Form 2. | 2013-05-16 |
20130122060 | USING BUCKY PAPER AS A THERAPEUTIC AID IN MEDICAL APPLICATIONS - Methods, systems, and uses of bucky paper are provided in the present invention. These embodiments include covering medical implants with single or multiple layers of bucky paper, treating bucky paper with various therapeutics to be released through the bucky paper to a target site, shaping bucky paper into non-conventional configurations for improved therapeutic deliver, and using bucky paper alone or in conjunction with other materials to treat a target site. | 2013-05-16 |
20130122061 | Delayed Release Tablet With Defined Core Geometry - A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released. | 2013-05-16 |
20130122062 | POLYMERIC COMPOSITIONS CONTAINING IR-EMITTING/ABSORBING ADDITIVES AND SHAPED ARTICLES COMPRISED THEREOF - Polymeric compositions containing additives having properties of emission and/or absorption of radiation in the long infrared region, and articles shaped therefrom are produced, including yarns and textile articles such as fabrics or knits; such additives include organic additives or inorganic fillers which have a capacity for absorption/emission of radiation in the infrared region, in a wavelength range of from 2 μm to 20 μm, and also a polymeric substrate, with the proviso that the inorganic fillers may be selected from among oxides, sulfates, carbonates, phosphates and silicates, and such inorganic fillers having an average particle size of less than 2 μm. | 2013-05-16 |
20130122063 | Nanotubes as Mitochondrial Uncouplers - A method of uncoupling mitochondria in a subject including administering nanotubes to the subject in a therapeutically effective amount, wherein the nanotubes are self-rectifying is provided. A method of decreasing reactive oxygen species and decreasing detrimental loading of Ca | 2013-05-16 |
20130122064 | Ophthalmic Depot Formulations for Periocular or Suconjunctival Administration - The present invention relates to ophthalmic depot formulations comprising an active agent, e.g. embedded in a pharmacologically acceptable biocompatible polymer or a lipid encapsulating agent, e.g. for periocular or subconjunctival administration. | 2013-05-16 |
20130122065 | Pharmaceutical Composition - Provided herein are pharmaceutical compositions comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. Methods for treating pain using such compositions are also demonstrated. | 2013-05-16 |
20130122066 | DRUG DELIVERY DEVICES AND GROWTH FACTOR FORMULATIONS FOR ACCELERATED WOUND HEALING - The present invention is directed to novel drug delivery devices and pharmaceutical compositions containing growth and differentiation factor proteins. Said devices and compositions are specifically designed to accelerate tissue regeneration and wound healing processes of mammalian tissues. The invention is especially useful for the supportive therapy of diabetic wounds and ulcers. | 2013-05-16 |
20130122067 | Growth-inhibited hydroxyapatite, process for its preparation and use - The invention relates to growth-inhibited hydroxyapatite for improving bone healing. It differs from the apatites employed to date in that it releases calcium ions and phosphate ions in physiological solutions, which, unlike traditional hydroxyapatites, it does not bind. It thereby promotes bone regeneration and bone growth. The growth-inhibited hydroxyapatite contains in agglomerates of prestructured collagen templates on which hydroxyapatite crystals with a crystallite growth of below its critical nucleus radius are formed epitactically. It is prepared by the steps a) mineralization of prestructured collagen templates in supersaturated Ca- and phosphate-ion-containing solutions, where the prestructured collagen templates are capable of diffusion and/or migration, so that HAP crystallites grow epitactically on the collagen templates and the collagen templates grown together with HAP crystallites agglomerate due to their capability of diffusion and/or migration, b) separating off the agglomerates. | 2013-05-16 |
20130122068 | THREADS OF CROSS-LINKED HYALURONIC ACID AND METHODS OF USE THEREOF - This disclosure relates generally to threads with improved properties comprising cross-linked hyaluronic acid, optimized methods of making such threads and uses thereof, for example, in aesthetic applications (e.g., facial contouring, soft tissue augmentation products), surgery (e.g., sutures), drug delivery, negative pressure wound therapy, moist wound dressing, and the like. | 2013-05-16 |
20130122069 | NANOFIBER LAMINATE SHEET - A nanofiber laminate sheet including a nano fiber layer containing a cosmetic component or a medicinal component and a water soluble base layer located on at least one side of the nano fiber layer. The water soluble base layer is less water-soluble than the nanofiber layer. The water soluble base layer is preferably constructed of nano fiber portions mingled with filmy portions. The water soluble base layer is preferably a layer of nanofibers in which nanofibers cohere to each other to form the filmy portions at their intersections. | 2013-05-16 |
20130122070 | BENEFIT DELIVERY PARTICLE, PROCESS FOR PREPARING SAID PARTICLE, COMPOSITIONS COMPRISING SAID PARTICLES AND A METHOD FOR TREATING SUBSTRATES - The invention provides a benefit agent delivery particle having an average diameter of less than 50 micron comprising; at least one shell formed by a step-growth polymerisation reaction, preferably involving an isocyanate monomer, more preferably a urethane and/or a urea, interior said shell, at least one region formed by chain-growth polymerisation reaction (preferably a free-radical polymerisation) which does not involve an isocyanate, c) optionally, a benefit agent interior to said shell, and/or a deposition aid exterior to said shell. The invention further provides a process for the preparation of such particles wherein the shell is formed prior to the chain-growth polymerisation of the at least one region interior of the shell, preferably be forming the shell at a temperature at which the chain-growth reaction is inhibited. The invention further provides fully formulated products, preferably liquids and gels, which contain said benefit agent delivery particles and a method of treating substrates using said products. | 2013-05-16 |
20130122071 | Composition in the Form of an Emulsion, Comprising a Hydrophobic Phase Dispersed in an Aqueous Phase - The present invention relates to a composition in the form of an emulsion, advantageously a Pickering emulsion, comprising a hydrophobic phase dispersed in an aqueous phase, which composition contains emulsifying particles capable of stabilizing said emulsion, at least some of said particles consisting of cellulose nanocrystals having an elongated shape, which have the following features: a length between 25 nm to 1 μm, and a width between 5 to 30 nm. | 2013-05-16 |
20130122072 | DELIVERY SYSTEM FOR ACTIVE COMPONENTS AS PART OF AN EDIBLE COMPOSITION - A delivery system for inclusion in an edible composition is formulated to have at least one active component with an encapsulating material for delivering the active component upon consumption of the edible composition wherein the dispersion of active component particles, as measured by the average distance between active component particles in the delivery system divided by the average particle diameter of the active component particles, is from 0.5 to 20. | 2013-05-16 |
20130122073 | COMPOSITION IN THE FORM OF LIQUID FOR MAINTENANANCE OF CONTACT LENSES AND MEDICAL MATERIALS - The invention relates to a composition, particularly in the form of liquid to be used externally as a rinsing contact lenses, containing nanocrystalline photocatalyst active in visible light, and optionally hydrogen peroxide. | 2013-05-16 |
20130122074 | Neutral, Stable and Transparent Photocatalytic Titanium Dioxide Sols - A method for preparing a neutral, stable and transparent photocatalytic titanium dioxide sol is provided. The method comprises (1) contacting an alkaline titanium dioxide sol with an alkaline peptizing agent to provide a peptized alkaline titanium dioxide sol; (2) neutralizing the peptized alkaline titanium dioxide sol; and (3) obtaining or collecting the neutral, stable and transparent photocatalytic titanium dioxide sol. The titanium dioxide sol is stable and transparent over a range of pH of about 7.0 to about 9.5. The titanium dioxide sol may include crystallites of titanium dioxide having an average particle size of less than about 10 nm with at least 90% of the crystallites being in the anatase form. | 2013-05-16 |
20130122075 | ENCAPSULATED TRANSFER FACTOR COMPOSITIONS AND METHODS OF USE - Methods for stress reduction comprising administering a transfer factor to an animal. The transfer factor can be combined with glucans, such as hybrid glucans and other components, to bring about stress reduction. The formulation is encapsulated when administered to adult ruminant. | 2013-05-16 |
20130122076 | Transdermal Patch Having Ultrasound Transducer for Administering Thrombolytic Reagents to Patients Having a Protein Misfolding Disease - The present invention relates to a method and device for treating patients with a Protein Misfolding Disease by chronically administering an effective dose of a thormbolytic reagent over an intermittent period of time. The thrombolytic reagents degrade the misfolded proteins that accumulate and that can become toxic in such patients. The administration is administered transdermally via a transdermal patch that is equipped with an ultrasound transducer for enhancing the penetration of the thrombolytic reagent into the bloodstream of a patient by increasing the permeability of the patient's skin. | 2013-05-16 |
20130122077 | SKIN PATCHES AND SUSTAINED-RELEASE FORMULATIONS COMPRISING LOFEXIDINE FOR TRANSDERMAL AND ORAL DELIVERY - This invention relates to a sustained release oral and transdermal pharmaceutical formulations and delivery systems comprising lofexidine. The invention is also directed to methods of treatment comprising administering lofexidine in a sustained release manner. Such methods can involve administration of the lofexidine containing compositions described herein. Compositions of lofexidine formulated for sustained release delivery are provided. Also provided are methods for the treatment of opiate addicts, migraine, neuropathic pain, and other therapeutic indications related to lofexidine. The methods may provide treatment for a variety of conditions amenable to amelioration by lofexidine administration. The methods utilize lofexidine compositions formulated for transdermal and sustained release oral delivery for administration of lofexidine in an amount effective for the treatment of the drug indications. | 2013-05-16 |
20130122078 | COLLAGEN-CONTAINING CELL CARRIER - The present invention relates to a method for the implantation of biological material into an organism. | 2013-05-16 |
20130122079 | TRANSDERMAL ADHESIVE COMPOSITIONS, DEVICES AND METHODS - A stable transdermal adhesive composition comprising: an adhesive comprising a washed polymerization reaction product of at least two ethylenically unsaturated monomers; and at least one pharmaceutically active compound which is susceptible to oxidative degradation; wherein the at least two ethylenically unsaturated monomers, if present in the adhesive as unreacted monomers, are present at a level of less than 200 ppm of total unreacted monomer, based upon the total weight of the adhesive, methods of making the composition, a transdermal drug delivery device using the composition, methods of making the device, and methods of delivery the pharmaceutically active compound are provided. | 2013-05-16 |
20130122080 | PHARMACEUTICAL COMPOSITION CAPABLE OF IMMUNO-REGULATION OR ENHANCEMENT OF IMMUNE RESPONSE - A pharmaceutical composition of immuno-regulation or enhancement of immune response is disclosed, which includes a liposome and an immuno-regulating molecule or an antigenic molecule. The liposome, the immuno-regulating molecule or the antigenic molecule needs no genetic or chemical modification. The immuno-regulating molecule or the antigenic molecule is spontaneously adsorbed by the liposome. Thus, the formed pharmaceutical composition can be used for immuno-regulation or enhancement of immune responses. | 2013-05-16 |
20130122081 | LIPOSOMES USEFUL FOR DRUG DELIVERY - The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provides methods of making the liposome compositions provided by the present invention. | 2013-05-16 |
20130122082 | Methods And Compositions For The Treatment And Prevention Of Aging-Associated Conditions - The present disclosure provides novel compositions and therapeutics and their methods of use. In particular, it relates to novel compositions and therapeutics expressing the Cisd2 gene and increasing Cisd2 protein activity as well as methods of using the compositions and therapeutics for treating or preventing aging-associated conditions. | 2013-05-16 |
20130122083 | DNA VACCINES ENCODING HEAT SHOCK PROTEINS - A method of treating a T cell-mediated inflammatory autoimmune disease by administering to an individual in need thereof an immunogenic composition comprising a recombinant construct of a nucleic acid sequence encoding heat shock protein 90 (HSP 90), or an active fragment thereof, wherein the nucleic acid sequence is operatively linked to one or more transcription control sequences. The disease is other than insulin dependent diabetes mellitus (IDDM) or rheumatoid arthritis. The administering of the immunogenic composition results in a shift of the immune response to a Th2 response, thereby treating the disease. | 2013-05-16 |
20130122084 | HYDROGEL - The invention is related to gel preparations capable of absorbing as well as releasing liquid, and the use of such gel preparations in the treatment of wounds. | 2013-05-16 |
20130122085 | PHARMACEUTICAL COMPOSITIONS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF - This invention provides a pharmaceutical composition comprising Compound I-V, including inter alia solid dosage forms of powder-filled capsule formulations, liquid-filled softgel capsules (softgels), tablets, and sustained release dosage forms, and uses thereof in treating a variety of diseases or conditions in a subject, for example, treating a muscle wasting disease and/or disorder, a bone related disease and/or disorder, metabolic syndrome, diabetes and associated diseases, and others. | 2013-05-16 |
20130122086 | METHOD FOR TREATING CELIAC DISEASE - Enteric compositions comprising one or more tight junction agonists and/or one or more tight junction antagonists are provided. Compositions of the invention may comprise a delayed-release coating disposed over a tight junction agonist and/or tight junction antagonist layer which may be disposed over an inert core. Delayed-release coatings may be substantially stable in gastric fluid and substantially unstable in intestinal fluid, thus providing for substantial release of the tight junction agonist and/or antagonist from the composition in the duodenum or jejunum of the small intestine. | 2013-05-16 |
20130122088 | TABLET FORMULATIONS CONTAINING 8-[-METHYL]-8-PHENYL-1,7-DIAZA-SPIRO[4.5]DECAN-2-ONE SALTS AND TABLETS MADE THEREFROM - Pharmaceutical formulations containing a salt of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I, which are suitable for forming into a tablet dosage form, as well as tablet dosage forms are disclosed. Disclosed also are methods of treatment utilizing such dosage forms. | 2013-05-16 |
20130122089 | DPP IV INHIBITOR FORMULATIONS - The present invention relates to pharmaceutical compositions of DPP IV inhibitors with an amino group, their preparation and their use to treat diabetes mellitus. | 2013-05-16 |
20130122090 | Multiple Unit Tablet Composition - A multiple unit tablet composition comprising an enteric coated multiple unit cores comprising a pharmaceutically active ingredient, wherein plasticizer content of enteric coating is less than about 10% by weight of the enteric coating polymer; at least two diluents and optionally one or more other pharmaceutically acceptable excipient, wherein one diluent is highly compactable microcrystalline cellulose and process for preparing the same. | 2013-05-16 |
20130122091 | POLYDEOXYRIBONUCLEOTIDE-BASED COMPOSITIONS AND THEIR METHODS OF USE - Compositions including synergistic combinations of polydeoxyribonucleotides and methyl amides, such as carnitine, are provided. Such compositions may include further optional active ingredients, such as a calcium salt, vitamins of the D or B groups, a sodium salt and a potassium salt, preferably used in combination. | 2013-05-16 |
20130122092 | THREE-PHASE CONTROLLED-RELEASE TABLET COMPRISING MELATONIN AND PROCESS OF PREPARATION - The invention relates, in one aspect, to a tablet having an internal core and external coating, both comprising melatonin and separated by an internal coating which does not comprise melatonin. The tablet is useful as a medicinal product, dietetic or food supplements for the treatment or as adjunctive therapy in sleep disorders. | 2013-05-16 |
20130122093 | FORMULATIONS OF A SRC/ABL INHIBITOR - The invention relates to pharmaceutical compositions of ′N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, and to methods of using the pharmaceutical compositions in the treatment of oncological and immunological disorders | 2013-05-16 |
20130122094 | SIALIC ACID ANALOGS - The present invention provides sialic acid analogs and their compositions useful for the treatment of sialic acid deficiencies. | 2013-05-16 |
20130122095 | PLATELET-DERIVED GROWTH FACTOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OSTEOCHONDRAL DEFECTS - The present invention provides compositions and methods for treating an osteochondral defect. In one embodiment, provided is a composition for treating an osteochondral defect comprising a biphasic biocompatible matrix and platelet derived growth factor (PDGF), wherein the biphasic biocompatible matrix comprises a scaffolding material and wherein the scaffolding material forms a porous structure comprising an osseous phase and a cartilage phase. In another embodiment, also provided is a method for treating an osteochondral defect in an individual comprising administering to the individual an effective amount of a composition comprising a biphasic biocompatible matrix and PDGF to at least one site of the osteochondral defect, wherein the biphasic biocompatible matrix comprises a scaffolding material and wherein the scaffolding material forms a porous structure comprising an osseous phase and a cartilage phase. | 2013-05-16 |
20130122096 | COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF MANUFACTURING AND USING SAME - Polymeric implants containing microparticles and nanoparticles, delivery of microparticles and nanoparticles from a polymeric implant is provided. | 2013-05-16 |
20130122097 | ANTIFUNGAL THERAPY - Described here are various compositions for the delivery active agents, e.g., antifungal agents. The compositions may be beneficial due to the particular release kinetics associated with them. Various locations and methods for placement of the compositions into the tissues of the nail unit, as well as tissues surrounding the nail unit are also described. | 2013-05-16 |
20130122098 | Method and composition to improve absorption of therapeutic agents - A tablet with an enhanced dissolution profile for a medicinally active ingredient such as aspirin and methods for making the tablet. The tablet comprises a blend of crystals of the medicinally active ingredient and a dissolution aid such as sodium or calcium carbonate or bicarbonate that coats the crystals upon co-milling. The blend is then compressed to form tablets that have an enhanced dissolution profile for the medicinally active ingredient. | 2013-05-16 |
20130122099 | POLYETHYLENE GLYCOL-COATED SODIUM CARBONATE AS A PHARMACEUTICAL EXCIPIENT AND COMPOSITIONS PRODUCED FROM THE SAME - Non-effervescent pharmaceutical compositions having at least one particle of carbonate coated by a layer of polyethylene glycol that substantially covers the at least one carbonate particle are described. Compositions are also described where the compositions include a weakly basic therapeutic agent, a first pH-modifying agent having at least one particle of carbonate coated by a layer of polyethylene glycol, and a second pH-modifying agent. The weakly basic therapeutic agent could be, but is not limited to, zolpidem or scopolamine. Compositions including zolpidem and scopolamine are used to treat insomnia and depression, respectively. | 2013-05-16 |
20130122100 | PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF - Nanoparticles comprising a prodrug and prodrugs linked to phospholipids, wherein the linkages facilitate release of the prodrugs from the nanoparticles to sites within a target cell or cell membrane by fusion of the particle and the cell membrane are disclosed. Also disclosed are methods for producing and using the nanoparticles and their constituents. | 2013-05-16 |
20130122102 | Delivery Systems For Improving Oral Bioavailability of Fenobam, Its Hydrates, And Salts - A delivery system for administration to a patient of Fenobam, its hydrates, and salts optimizes solubility and dissolution properties of Fenobam, its hydrates, and salts using either microemulsions, solid dispersions, cyclodextrin, gastroretentives, enteric coatings, and sustained delivery techniques to provide a vehicle for oral administration of these drugs. | 2013-05-16 |
20130122103 | ELECTROSTATICALLY BONDED VESICLE - The purpose of the present invention is to provide an electrostatically bonded vesicle which bears disulfide bonds or thiol groups. The present invention relates to a vesicle having a membrane which is formed from both a first polymer of (a) or (b) and a second polymer of (c) or (d) (with the proviso that a combination of (b) and (d) is excepted) and in which the cationic segment and anionic segment of the polymers are partially crosslinked. First polymer: (a) a block copolymer (I) having both an electrically non-charged hydrophilic segment and a cationic segment, (b) an amino acid polymer (I) having a cationic segment. Second polymer: (c) a block copolymer (II) having both an electrically non-charged hydrophilic segment and an anionic segment, (d) an amino acid polymer (II) having an anionic segment. | 2013-05-16 |